Hussein Mohamad A, Juturi Jaya V, Lieberman Isador
Myeloma Research Program, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio 44195, USA.
Curr Opin Oncol. 2002 Jan;14(1):31-5. doi: 10.1097/00001622-200201000-00006.
Multiple myeloma is a clonal B-cell tumor of slowly proliferating plasma cells within the bone marrow. Among hematologic malignancies, it constitutes 10% of the cancers and ranks as the second most frequently occurring hematologic cancer in the United States, after non-Hodgkin lymphoma. Interleukin-6 is an important cytokine in myeloma cell growth and proliferation. Close cell-to-cell contact between myeloma cells and the bone marrow stromal cells triggers a large amount of interleukin-6 production, which supports the growth of these cells, as well as protecting them from apoptosis induced by dexamethasone and other chemotherapeutic agents. Therapies modulating the tumor and its microenvironment are being actively pursued with the goal of converting multiple myeloma to a chronic disease with the patients maintaining a normal lifestyle.
多发性骨髓瘤是一种骨髓内缓慢增殖的浆细胞的克隆性B细胞肿瘤。在血液系统恶性肿瘤中，它占癌症的10%，在美国是仅次于非霍奇金淋巴瘤的第二常见血液系统癌症。白细胞介素-6是骨髓瘤细胞生长和增殖中的一种重要细胞因子。骨髓瘤细胞与骨髓基质细胞之间紧密的细胞间接触会触发大量白细胞介素-6的产生，这不仅支持这些细胞的生长，还能保护它们免受地塞米松和其他化疗药物诱导的凋亡。目前正在积极探索调节肿瘤及其微环境的疗法，目标是将多发性骨髓瘤转变为一种慢性病，使患者能够维持正常生活方式。
